Technology and Strategy Roundtables will run from 12:00-12:45 with 15 minutes for a quick summary from each table at the front of the room. These will take place in the conference rooms: look for your table number to participate.
1. Raw material supply for the commercial manufacturing of cell and gene therapies
An Exosome-based Drug Delivery Platform Derived from a Human Neural Stem Cell (hNSC) Line
To ensure the scale required for clinical research and commercialisation producer cell immortalisation and clonal isolation is a practical strategy to produce consistent, functionally bioactive exosomes for use as therapeutic agents.
The cell line can be rapidly modified to alter exosome cargo or reprogrammed to change its phenotype while maintaining its conditional immortalisation.
hNSC derived exosomes demonstrate favourable distribution across the blood brain barrier.